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INTRODUCTION
Interleukin-1 (IL-1), first recognized as an endogenous
pyrogen, has subsequently been found to be an important
mediator of immune and inflammatory reactions (1-3). It is
synthesized in response to infection, injury or antigenic
challenge by a variety of cells including monocytes and
macrophages (2), and exerts biologic effects on various
target cells in normal and pathological conditions (1-3).
IL-1 exists as two genomic forms, IL-1α and IL-1β, both of
which are very similar in function. Although the precussor
for IL-1β requires cleavage to reveal its IL-1 activity, the
proIL-1α is fully active as a precussor and remains
intracellulaly (1-3). IL-1α is thought to be involved in
cell-mediated responses through cell-to-cell contact
(1-3). Despite its host-defense role, IL-1 may cause
tissue damage and exacerbate chronic inflammation.
Accordingly, its potent inflammatory effects are believed
to be tightly regulated.
The actions of IL-1 are controlled in several ways, such
as by regulation of its synthesis and by production of
neutralizing factors including a soluble IL-1 receptor, and
an IL-1 receptor antagonist (1, 3, 4, 7). Recently, antibodies
against cytokines such as interferons, tumor necrosis
factor, IL-6 and IL-10 have been detected in sera of
patients with inflammatory and neoplastic diseases and in
healthy subjects (8-12). Autoantibodies against IL-1α
(IL-1α autoantibodies) have also been found in the sera of
patients with inflammatory process and asymptomatic
individuals (5, 6, 13-16). It is known that IL-1α auto-
antibodies neutralize IL-1α specifically (14, 16, 17), while
IL-1 receptor antagonist blocks the activity of both IL-1α
and IL-1β (1, 3). However, the level of plasma IL-1α
autoantibodies which neutralizes IL-1α activity was not
clear. Thus, the role of IL-1α autoantibodies in blood
remains to be defined. However, the reported prevalence
of IL-1α autoantibodies in the blood of healthy subjects
was inconsistent (6, 13-16). Their frequency of occurrence
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in normal human blood needs to be established, because
fresh plasma is transfused into patients as an element of
blood, and also because such data sheds light on the roles
of IL-1α autoantibodies in healthy and diseased subjects.
We developed sensitive radioimmunoassay (RIA) for
IL-1α autoantibodies, and measured IL-1α autoantibodies
levels in plasma from a large number of healthy blood
donors, considering overall prevalence, sex and age.
Furthermore, we characterized the immunoglobulin class
of IL-1α autoantibodies as well as elucidating the level of
plasma IL-1α autoantibodies to neutralize IL-1α activity.
MATERIALS AND METHODS
Study Population
Plasma was obtained from donor blood at the
Tokushima Blood Transfusion Center in Japan. Samples
were obtained from 6290 healthy donors (2313 women
and 3977 men between 16 yr and 64 yr). Samples were
separated into donor groups I-VI, respectively aged 16-19,
20-29, 30-39, 40-49, 50-59, and 60-64 yr. Age and sex
distributions of donors are shown in Table 1.
Measurement of IL-1α autoantibodies
Human recombinant IL-1α (rIL-1α) was prepared as
described previously (18). IL-1α autoantibodies in plasma
were measured by a radioimmunoassay (RIA). Briefly,
duplicate 50 μl samples of plasma or standard dilutions of
monoclonal antibodies to IL-1α (ANOC 301, purity >95%),
ranging from 5 to 640 ng/ml, were mixed with 125I-rIL-1α.
Each sample was mixed with 0.1% bovine serum albumin/
phosphate buffer saline (BSA/PBS) containing 5 mM
ethylenediaminetetraacetic acid (EDTA)/0.05% NaN3, and
each standard dilution of rIL-1α was mixed with 0.1%
BSA/PBS containing 5 mM EDTA/0.05% NaN3 and carrier
buffer (2% bovine γ globulin). After antigen-antibody
binding had reached equilibrium by overnight incubation
at room temperature, each sample was mixed with 25%
polyethylene glycol (MW 6000) and incubated for 1hr.
Then, the tubes were centrifuged at 3000 rpm for 15 min,
and the radioactivity of the precipitates were counted for 1
min in an automated γ-spectrometer. The IL-1α
autoantibodies titer was determined from the standard
dilution curve using IL-1α monoclonal antibody (Fig.1).
Plasma was considered IL-1α autoantibodies-positive at
levels over 5 ng/ml. Autoantibodies for IL-1β (IL-1β
autoantibodies) in the plasma were measured by the same
method as described for IL-1α autoantibodies, substituting
IL-1α by IL-1β. The sensitivity of this assay for IL-1β
autoantibodies was 5 ng/ml.
Characterization of IL-1α autoantibodies in plasma
To characterized IL-1α autoantibodies, we used plasma
containing a high IL-1α autoantibodies level and investi-
gated immunoglobulin class of IL-1α autoantibodies. The
plasma was applied to a protein A agarose column. After
washing with the binding buffer (50 mM sodium borate
with 3M NaCl, pH 9.0), the bound material was eluted
with elution buffer (100 mM glycine, pH 2.5) and collected
in 2 ml fraction. The IL-1α autoantibodies level in each
fraction was measured by RIA. The plasma IL-1α
autoantibodies was also fractionated by gel filtration using
Sepharose 6B column. Plasma was applied to a column
preequilibrated with 50 mM Tris-HCl containing 0.5 M
NaCl and 5 mM EDTA (pH 8.0) and eluted with the same
buffer. The elute was collected in 3 ml fractions and the
IL-1α autoantibodies concentration of each fraction was
measured by RIA.
IL-1α receptor assay
Neutralizing activity of IL-1α autoantibodies in plasma
was examined by IL-1 receptor assay as described
previously (19). 125I-labeled IL-1α was prepared by the
same way as described in the method of RIA. The specific
activity of 125I-labeled IL-1α was 130-150 μCi/g. BALB/3T3
fibroblasts (the American Type Culture Collection) were
maintained in a Dulbecco's minimum essential medium
(Nissui Pharm. Co. Ltd., Tokyo, Japan) containing 10%
fetal calf serum (Hyclone Inc., Utah). 3T3 fibroblasts
(1 X 106) were incubated with 500 μl of culture medium
containing 125I-labeled IL-1α (105cpm) and 10% sera from
the patients in 12-well plates (Corning Glass Works, NY)
for 2 hr at 4. Nonspecific binding was determined in the
presence of 1 μg/ml of unlabeled IL-1α. The cell
monolayers were then rinsed 3 times with 1 ml of PBS
Table 1. Distributions by age and sex of blood donors
Fig.1. Standard curve of IL-1α autoantibodies by RIA. The standard
dilution of IL-1α monoclonal antibody (ANOC 301), ranging from 5
to 640 ng/ml, were mixed with 125I-labeled rhIL-1α. The mixture was
centrifuged and precipitates were counted by γ-spectrometer. B/T
(%) : the percentage of bound 125I-labeled IL-1α (B)/total 125I-labeled
IL-1α. (T).
Group Age (ys) Males Females Total






16-19
20-29
30-39
40-49
50-59
60-64
711
844
1032
947
389
54
546
446
484
479
300
58
1257
1290
1516
1426
684
112
Total 3977 2313 6290
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then solublized with 1 ml of a mixture of 1% SDS and 0.2 N
NaOH. The radioactivity was counted in a γ-counter.
Equilibrium binding assay
To determine the affinity of IL-1α autoantibodies in
plasma for human IL-1α, the dissociation constant (Kd) of
IL-1α autoantibodies/IL-1α complexes was measured. The
plasma IL-1α was incubated with increasing amount of
125I-IL-1α in the final volume of 200 μl in RPMI 1640, 1%
BSA. After 4 hr incubation at 4, IL-1α autoantibodies/
IL-1α complexes were precipitated with protein
G-sephadex and the radioactivity of the precipitate was
measured by a γ counter. Ratio (B/F) of specific bound
125I-IL-1α (B) vs free 125I-IL-1α (F) were calculated, then
plotted vs specific bound 125I-IL-1α amounts calculated
according to the IL-1α specific activity. According to
Scatchard, the Kd value was determined by the slope of
the obtained straight line (Kd=-1/slope) and expressed in
concentration according to the reaction volume.
Statistical Analysis
Statistical analysis was performed by the χ 2 test, and
values were considered significantly different at p<0.05.
RESULTS
Standard curve of IL-1α autoantibodies in RIA
The standard curve of IL-1α autoantibodies, as
measured by RIA, is shown in Fig.1. From this standard
curve, the IL-1α autoantibodies concentration in plasma of
normal healthy subjects was calculated, and ranged from
5 to 640 ng/ml by this assay.
Prevalence of IL-1α and β autoantibodies in normal
human plasma
Prevalence of IL-1α autoantibodies in plasma are shown
in Table 2. IL-1α autoantibodies was detected in 917
(14.6%) of samples. Its prevalence was higher in males
than in females in general (16.6% vs 11.2%, p<0.01) and in
groups II and IV (p<0.01). As shown in Table 2, the
prevalence of IL-1α autoantibodies increased with age : in
groups I and II, it was less than those in groups III, IV, V
and VI (p<0.01), but there were no significant differences
in the groups over 40 yr. In a parallel study, we measured
IL-1β autoantibodies in plasma from about 500 normal
subjects. We could not detect IL-1β autoantibodies in
plasma from any subjects (data not shown).
Distribution of subjects with high titers of IL-1α
autoantibodies in the blood
The proportions of subjects with an IL-1α
autoantibodies level exceeding 1000 ng/ml among the
antibody-positive individuals are shown in Figure 2. The
percentage of subjects with a high titer of IL-1α
autoantibodies increased steadily with age, being 2 (2.9%)
in group I, 8 (6.1%) in group II, 27 (10.9%) in group III, 41
(13.2%) in group IV, 27 (19.7%) in group V and 7 (29.2%) in
group VI.
Characterization of plasma IL-1α autoantibodies
To characterize IL-1α autoantibodies, we used plasma
containing a high IL-1α autoantibodies level. The sample
was applied to a protein A agarose column. After washing
with the binding buffer, we obtained the IgG fraction
using an elution buffer. RIA showed that the high titer of
IL-1α autoantibodies was presented only in the IgG
fraction (Fig.3). Furthermore, the plasma was fractionated
by gel filtration resulting in its elution with an apparent
molecular weight of 100,000-200,000, IL-1α autoantibodies
corresponded to that of IgG (Fig.4). The affinity of the
IL-1 α autoantibodies in several samples, examined by the
Scatchard analysis, was between 2.1 X 10-10 and 1.2 X 10-9
M (Table 3).
Neutralizing activity of IL-1α autoantibodies
First, we examined whether neutralizing activity of
IL-1α autoantibodies was estimated by IL-1α receptor
assay using BALB/3T3 fibroblasts.
Standard of IL-1 receptor assay
was performed using monoclonal
antibody to IL-1α (ANOC 301).
As shown in Fig.5, monoclonal
antibody (ANOC 301) showed
neutralizing activity in a dose
dependent manner. Next, to
examine the neutralizing activity
of IL-1α autoantibodies in plasma,
we performed an IL-1α receptor
assay. Plasma from subjects with
a concentration of IL-1α auto-
Table 2. Incidences of antibodies to IL-1α in blood donors
Date show percentages of positive cases in males and females in each in group.
a) p<0.01, significance difference between males and females.
b) p<0.001, significance difference between Group and Groups-.
c) p<0.001, significance difference between Group and Groups-.
Fig. 2. Distribution of normal individuals with high plasma titers of
IL-1α autoantibodies. Bars show percentages of subjects with IL-1α
autoantibody levels of over 1000 ng/ml among the antibody-positive
cases.
Group
16-19 ys
Group
20-29 ys
Group
30-39 ys
Group
40-49 ys
Group
50-59 ys
Group
60-64 ys
Total
Males
Females
6.0
4.8
12.4a)
5.8
17.3
13.2
24.6a)
14.5
22.6
19.0
22.2
19.0
16.6a)
11.2
Total 5.5b) 10.2c) 16.0 21.5 21.0 20.5 14.6
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antibodies, whose level was over 1000 ng/ml, blocked
binding of 125I-labeled IL-1α to the IL-1 receptor, showing
neutralizing activity against IL-1α (Fig.6). Plasma levels of
IL-1α autoantibodies much less than 1000 ng/ml or
without detectable titers showed no detectable neutral-
izing activity.
DISCUSSION
High-affinity specific autoantibodies to various cytokines,
Fig. 3. Fractionation of plasma IL-1α autoantibodies by a protein A
agarose column. Plasma with high IL-1α autoantibody levels were
diluted and applied to the protein A column. After washing with the
binding buffer, protein was eluted in 2 ml fractions by an elution
buffer. Then, the IL-1α autoantibodies level in each fraction was
measured by RIA as described in Methods.
Table 3. Affinity constant of IL-1α autoantibodies in high titers
subjects
Fig. 4. Analysis of IL-1α autoantibodies by gel filtration. Plasma
with high levels of IL-1α autoantibody were fractionated by gel
filtration using Sepharose 6 B column. The titer of the IL-1α
autoantibody in each fraction was measured by RIA as described in
Methods. Closed circle indicated concentrations of protein in
each fraction as determined by OD 280 ; open circle indicated
concentrations of IL-1α autoantibodies in each fraction. Molecular
marker : A ; Ferritin (440 Kd), B ; IgG (160 Kd), D ; albumin (68
Kd).
Fig. 6. Neutralizing activity of IL-1α autoantibodies in plasma.
BALB/3T3 fibroblasts were incubated with 125I-labeled IL-1α in the
presence of plasma from normal subjects. Cells were rinsed and
solubilized and then the radioactivity was counted. The subjects
with a high titer of IL-1a autoantibody, whose level was over 1000
ng/ml, showed neutralizing activity.
Fig. 5. A standard of IL-1α receptor assay. BALB/3T3 fibroblasts
were incubated with 125 I-labeled IL-1α for 2 hr in the presence of
the indicated concentrations of monoclonal antibody to IL-1α
(ANOC 301), which has neutralizing activity for IL-1α. Cells were
rinsed and solubilized, and then the radioactivity was counted using
a γ-counter.
Donor Affinity constant
（×１０‐１０M)
１
２
３
４
５
６
７
８
９
１０
１１
１２
7.41
6.21
5.03
6.95
3.10
11.71
2.07
7.17
7.56
3.83
5.88
10.30
Average 6.4
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such as IL-1α, IL-6, IL-10 and interferon, are known to be
present in normal individuals (5, 6, 8-16). Recently,
pharmaceutical preparations of human IgG were reported
to contain antibodies against these cytokines (20, 21),
indicating that blood products containing these antibodies
are likely to be transfused into patients and making it
necessary to clarify the prevalence of these antibodies in
donor blood.
Despite several reports on the presence of IL-1α
autoantibodies in normal subjects, its prevalence has been
discrepant (6, 13-16). Furthermore, age-associated altera-
tions in humoral immunity have been recognized widely,
with aging associated with a decline in antibodies against
pathogens and an increase in autoantibodies (22, 23).
Although Hansen et al. reported that by a second-antibody
precipitation assay, the prevalence of IgG antibodies
against IL-1α depended on both sex and age (24), the
number of subjects was apparently not enough to
conclude the relation between the prevalence of IL-1α
autoantibodies and age or sex. Therefore, to clarify the
prevalence of IL-1α autoantibodies, we measured the level
of IL-1α autoantibodies in plasma from a large number of
healthy blood donors by RIA.
We found that about 15% of plasma samples from
healthy donors contained detectable IL-1α autoantibodies
at a level of over 5 ng/ml. Similar to other autoantibodies,
their prevalence increased with age. We found their
prevalence to be higher in males than in females, an
unexpected difference. Therefore, the contradiction in the
earlier reports concerning the prevalence of IL-1α
autoantibodies may be due to the differences in the age
and sex of the subjects studied. Samples with a high level
of IL-1α autoantibodies (>1000 ng/ml) increased
with age. However, we could not detect any IL-1β
autoantibodies in plasma. With column chromatography,
IL-1α autoantibodies eluted with an apparent molecular
weight of 100,000-200,000 and corresponding to a subclass
of the IgG fraction. Moreover, a substantial amount of this
material bound to protein A which binds with high
specificity to the Fc regions of IgG 1, IgG 2 and IgG 4
(25). These results suggested that IL-1α autoantibodies
were of the IgG class and our results were similar to
previous reports (13, 17, 26).
The role of IL-1α autoantibodies is still unknown, but
reported effects include inhibition of the biologic activity
of IL-1α but not IL-1β (5, 14, 17). It has been shown that
Fab fragments of the antibodies bind with high affinity to
human recombinant IL-1α (13, 27), and that they interfere
with its T-cell stimulatory function (26). We confirmed
that the plasma containing high titers of this antibodies
blocked binding of 125I-labeled IL-1α to IL-1 receptors on
the surface of BALB/3T3 fibroblasts. Our results showed
that IL-1α autoantibodies neutralize IL-1α which is
consistent with other reported results (14, 16, 17). We
showed that a level of IL-1α autoantibodies over
1000 ng/ml of plasma was needed to neutralize IL-1α. The
affinity of the IL-1α autoantibodies in plasma examined by
Scatchard analysis showed high affinity, which suggested
that this antibody may play a physiological role against
overproduced IL-1α .
Although the production of antibodies against IL-1α in
healthy subjects can not be adequately explained, there
are some interesting reports. IL-1α has been demon-
strated in various body fluids and tissues, and is produced
by keratinocytes and alveolar macrophages (2). IL-1α is
thought to function through cell-to-cell interaction and
to be involved in local immune reactions (1-3). It is
suggested that IL-1α autoantibodies in some healthy
subjects, produced in response to IL-1α presented in
normal tissues, helps to hold the immunoinflammatory
processes involving IL-1α in check. Furthermore, IL-1α
autoantibodies may inhibit the systemic reaction of excess
proIL-1α which has a biological function and increase in
these processes. It was not clear why the prevalence of
IL-1α autoantibodies in plasma was increased with age.
Recently, the relation between cytokine and aging was
reported (28, 29). Catania et al. showed the plasma
concentration of IL-1 receptor antagonist and soluble TNF
receptor were greater in healthy aged subjects than
younger controls (29). We suppose that unapparent
inflammation in aged subjects may cause cell activation
and release of cytokine antagonist including IL-1
receptor antagonist, soluble TNF receptor and IL-1α
autoantibodies.
In this study, we demonstrated the prevalence of IL-1α
autoantibodies in plasma from a large number of healthy
blood donors in general and by age and sex. These results
would suggest that monitoring the blood donor pools for
level of IL-1 α autoantibodies would be useful in disease
states. Recently, cytokine inhibitor included the IL-1
receptor antagonist and the soluble IL-1 receptor was
administrated to patients with immunoinflammatory
diseases as a new therapeutic approach (3, 30, 31). In this
regard, high concentrations of IL-1 α autoantibodies
which were prepared from normal subjects may be useful
as a new type of IL-1α antagonist.
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